EGFR-tyrosine kinase inhibitors (TKIs) therapy is the mainstay treatment modality for patients with locally-advanced unresectable or metastatic non-small cell lung cancer (NSCLC) (Park et al., 2020; Wu et al., 2019). Here, EGFR is linked to non-small cell lung carcinoma.